Immunobiology Of Natural Killer Cells

Volume 2
1. Auflage 2019
ISBN: 978-0-367-25554-1
Verlag: Taylor & Francis Ltd

Buch, Englisch, 242 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 603 g

Reihe: Routledge Revivals

First published in 1986: This book contributes to the advancing knowledge of reads in the field of NK cells, and will be helpful as a teaching device.

Autoren/Hrsg.

Lotzová, Eva

Weitere Mitwirkende

Herberman, Ronald B.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Medizin, Gesundheit: Sachbuch, Ratgeber

Inhaltsverzeichnis

1. In Vivo Activities of NK Cells Against Primary and Metastatic Tumors in Experimental Animals
Nabil Hanna
2. The Involvement of Natural Killer Cells in Human Malignant Disease
Hugh Pross
3. Impaired NK Cell Profile in Leukemia Patients
Eva Lotzova, Cherylyn A. Savary, and Ronald B. Herberman
4. In Vivo Modulation of NK Activity in Cancer Patients
Peter M. Moy and Sidney H. Golub
5. The Implications of Aberrant Natural Killer (NK) Cell Activity in Nonmalignant Chronic Diseases
Jean E. Merrill
6. NK Cell Role in Regulation of the Growth and Functions of Hemopoietic and Lymphoid Cells
Eva Lotzova
7. Natural Killer Cells Active Against Viral, Bacterial, Protozoan, and Fungal Infections
Patricia A. Fitzgerald and Carlos Lopez
8. Cytokine Secretion and Noncytotoxic Functions of Human Large Granular Lymphocytes
Guiseppe Scala et al.
9. Augmentation of Natural Killer Activity
John R. Ortaldo and Ronald B. Herberman
10. Regulation of NK Cell Activity by Suppressor Cells
Eva Lotzova and Cherylyn A. Savary
11. NK Cell Cloning Technology and Characteristics of NK Cell Clones
Colin G. Brooks
12. A Comparison of Antibody-Dependent Cellular Cytotoxicity (ADCC) and NK Activity
Andrew V. Muchmore

Über Autor(innen)

Dr. Eva Lotzova is Professor of Immunology, Chief of the Division of Immunologenetics at the University of Texas System Cancer, M.D. Anderson Hospital and Tumor Institute, Houston.
Dr. Ronald B. Herberman, formerly Chief of Biological Therapeutics Branch and Acting Associate Director for the Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, Frederick, Maryland.